What development phase is Nandron in?

Nandron is FDA-approved (marketed).

What is the generic name of Nandron?

EMORFAZONE is the generic (nonproprietary) name of Nandron.

Last reviewed 2026-04-20 · How we verify

Nandron (EMORFAZONE)

FDA-approved active Small molecule Quality 13/100

Emorfazone (Nandron) is a marketed drug primarily indicated for pain management, leveraging a unique mechanism of action that modulates pain perception through specific cellular interactions. The key composition patent for Emorfazone is set to expire in 2028, providing a clear period of market exclusivity and potential revenue stability. However, the lack of detailed revenue data and key trial results poses a significant risk in assessing the drug's long-term market performance and competitive positioning.

At a glance

Generic name	EMORFAZONE
Drug class	emorfazone
Modality	Small molecule
Therapeutic area	Pain
Phase	FDA-approved

Approved indications

Pain

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Nandron CI brief — competitive landscape report
Nandron updates RSS · CI watch RSS